Robert W. Baird analyst Brian Skorney maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) on June 23 and set a price target of $110.00. The company's shares closed last Monday at $76.30. According to TipRanks.com, Skorney has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -8.6% and a 40.0% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and Enanta Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $123.29 average price target, implying a 62.7% upside from current levels.
https://www.tipranks.com/news/blurbs/sarepta-therapeutics-srpt-gets-a-buy-rating-from-robert-w-baird-3?utm_source=advfn.com&utm_medium=referral
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Sarepta Therapeutics Charts.
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Sarepta Therapeutics Charts.